Imatinib-sensitive KIT mutant tumors contained greater frequencies of CD3 + and CD8 + T cells, but a lower percentage of CD4 + T cells and T regs compared to imatinib-resistant KIT mutant GIST tumor mouse models. Here, KIT is linked to neoplasm.